China-based DaAn Gene Co., Ltd, (SHE: 002030) affiliated with Sun Yat-sen University, has announced that it has received a Category III medical device license from the National Medical Products Administration (NMPA) for its genetic deafness gene detection kit, which employs PCR flow cytometry fluorescence hybridization methodology.
Advanced Technology for Genetic Hearing Loss Detection
The product utilizes flow cytometry fluorescence hybridization technology to detect 17 mutation sites across 4 genetic hearing loss genes in the genomic DNA derived from dry blood spot samples. This advanced testing method provides auxiliary diagnostic insights into genetic hearing loss and complements routine physical hearing screenings.
Enhancing Hearing Loss Detection and Prevention
The test results from DaAn Gene’s detection kit serve as a valuable tool in identifying individuals with genetic predispositions to hearing loss. It is particularly effective in detecting drug-induced hearing loss gene carriers and those with delayed onset hearing loss, who may not be identified through standard physical hearing screenings. This capability enhances the early detection and prevention of hearing loss, offering a significant advancement in genetic testing and personalized medicine.-Fineline Info & Tech
